About this trial
Previous studies have confirmed the great potential of quantitative fluorescence molecular endoscopy (qFME) when looking at additional lesion detection initially missed by high-definition white light endoscopy (HD-WLE) for surveillance of Barrett's esophagus.
Eligibility criteria
Qualifiers
BE patients without dysplasia and with suspected/diagnosed low-grade dysplasia (LGD), high-grade dysplasia (HGD) or superficial EAC and planned diagnostic and/or therapeutic endoscopy
Written informed consent is obtained
Disqualifiers
Patients under the age of eighteen.
Submucosal and invasive EAC, also defined as EAC with tumor, node and metastasis (TNM)-classification other than T1.
Previous radiation therapy for esophageal cancer
Known immunoglobulin allergy
Trial design
Treatments tested in this trial
- Avastin
- Erbitux
- Fluorescence endoscopy and multi-diameter single fiber reflectance/single fiber fluorescence (MDSFR/SFF) spectroscopy
Treatment groups
Locations
1Sponsors and collaborators
University Medical Center Groningen
Lead sponsor